cancer

send to a friend share this

Paper from a research group in i3S wins the first edition of Prémio Cancro Gástrico IPO do Porto

The paper entitled "A panel of intestinal differentiation markers (CDX2, GPA33, and LI‑cadherin) identifies gastric cancer patients with favourable prognosis" from the Differentiation & Cancer group at i3S has won the first edition of "Prémio Cancro Gástrico IPO do Porto", an award for the best article in gastric cancer research published in the past 2 years assigned by IPO Porto. The award ceremony will take place at IPO Porto on May 31st, 2021.

Artigo de um grupo de investigação do i3S vence 1ª edição do Prémio Cancro Gástrico IPO do Porto

O artigo intitulado "A panel of intestinal differentiation markers (CDX2, GPA33, and LI‑cadherin) identifies gastric cancer patients with favourable prognosis" do grupo Differentiation & Cancer, no i3S, foi galardoado com a primeira edição do "Prémio Cancro Gástrico IPO do Porto", um prémio para o melhor artigo em investigação em cancro gástrico publicado nos últimos 2 anos e atribuído pelo IPO do Porto. A cerimónia de entrega do prémio terá lugar no IPO do Porto, no próximo dia 31 de Maio.

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.

Transcriptome Reprogramming of CD11b+ Bone Marrow Cells by Pancreatic Cancer Extracellular Vesicles


Joana Maia1,2, Andreia Hanada Otake1,3, Juliana Poças4,5,6, Ana Sofia Carvalho7, Hans Christian Beck8, Ana Magalhães4,5, Rune Matthiesen7, Maria Carolina Strano Moraes1 and Bruno Costa-Silva1

1-Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal

2-Graduate Program in Areas of Basic and Applied Biology, University of Porto, Porto, Portugal

Transcriptome Reprogramming of CD11b+ Bone Marrow Cells by Pancreatic Cancer Extracellular Vesicles

O cancro de pâncreas é a quarta principal causa de mortes relacionadas ao cancro no mundo, apresentando uma taxa de sobrevida de 5 anos de cerca de 6% e uma taxa de sobrevida média de cerca de 6 meses. Entre os cancros pancreáticos, o adenocarcinoma ductal pancreático (CP) é o tipo mais comum e é responsável por mais de 90% dos casos. Uma combinação de fatores leva ao mau prognóstico do CP, incluindo dificuldades na deteção da doença em estágio inicial, seu alto potencial metastático e sua resistência às terapias convencionais.

ISCaM2020 webinar series:Systemic Metabolism and Cancer 1: Cancer Therapy and Diet

Oct 20, 2020 04:00 PM London

Please click the link below to join the webinar:
https://crick.zoom.us/j/63151976897?pwd=ejNSV0dBdFF5V0J6SHF5STVRa3Y3dz09
Passcode: 680444

ISCaM2020 webinar series:Systemic Metabolism and Cancer 1: Cancer Therapy and Diet

Oct 20, 2020 04:00 PM London

Please click the link below to join the webinar:
https://crick.zoom.us/j/63151976897?pwd=ejNSV0dBdFF5V0J6SHF5STVRa3Y3dz09
Passcode: 680444

The multi-factorial nature of clinical multidrug resistance in cancer

Several experts from COST Action STRATAGEM - “New diagnostic and therapeutic tools against multidrug resistant tumors”, joined efforts to write an up-to-date, focused and thought-provoking review on the multi-disciplinary and interdisciplinary features of multidrug resistant cancers. It is necessary to identify and understand the various molecular mechanisms behind clinical multidrug resistance, in order to develop new targeted therapeutic strategies to overcome cancer therapeutic failure.

A natureza multifatorial da resistência a múltiplos fármacos anticancerígenos na prática clinica

Vários especialistas da Acção COST STRATAGEM - “New diagnostic and therapeutic tools against multidrug resistant tumors”, reuniram esforços para escrever uma revisão atualizada, desafiante e focada nas características multidisciplinares e interdisciplinares dos cancros com resistência a múltiplos fármacos. É necessário identificar e entender os vários mecanismos moleculares responsáveis pela resistência clínica a múltiplos fármacos anticancerígenos, de modo a desenvolver novas estratégicas terapêuticas dirigidas que permitam ultrapassar a falência da terapêutica.